Pharmakon—Danish College of Pharmacy Practice

Evolus Reports Second Quarter 2023 Results and Provides Business Update

Retrieved on: 
수요일, 8월 2, 2023
General Health, Health, Cosmetics, Retail, Pharmaceutical, Acceleration, Exercise, Trial of the century, Depreciation, Growth, Pharmakon—Danish College of Pharmacy Practice, Data, Renewable energy, Pharmaceutical industry, Insurance, Cryptocurrency, Bank

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.
  • Loss from operations for the second quarter of 2023 was $15.1 million, which included the $4.4 million license milestone expense, compared to $12.0 million in the first quarter of 2023.
  • Excluding the milestone expense, non-GAAP loss from operations in the second quarter of 2023 declined compared to the $5.9 million non-GAAP loss from operations recorded in the first quarter of 2023.
  • Net cash used for operating activities in the second quarter of 2023 was lower than the first quarter of 2023, representing continued progress toward cash flow breakeven.

Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese

Retrieved on: 
화요일, 5월 9, 2023
Biotechnology, General Health, Pharmaceutical, Health, 1969–70 1. Slovenská národná hokejová liga season, Neurotoxin, Partnership, Hyaluronic acid, History, Pharmakon—Danish College of Pharmacy Practice, Filler (linguistics), Safety, Pharmaceutical industry, Cryptocurrency

As a result of this product expansion, the company has raised its 2028 revenue outlook by $200 million to $700 million.

Key Points: 
  • As a result of this product expansion, the company has raised its 2028 revenue outlook by $200 million to $700 million.
  • “Today’s announcement represents a material step in achieving our goal of transforming Evolus into a multi-product aesthetics company,” said David Moatazedi, Evolus’ President and Chief Executive Officer.
  • “We are excited to expand our portfolio with Evolysse™, a highly competitive filler line that complements our fast-growing aesthetic neurotoxin, Jeuveau®.
  • “We are particularly excited to partner with Evolus in bringing our next-generation HA filler product line to the U.S.

BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
수요일, 5월 3, 2023
PIK, SG, BioCryst Pharmaceuticals, C2, RESEARCH, HAE, Pharmakon—Danish College of Pharmacy Practice, Patient, Investment, Webcast, R, Research, PARK, Pharmaceutical industry, Video game, Athyrium

RESEARCH TRIANGLE PARK, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Key Points: 
  • New patient growth remained strong, with a 20 percent increase in U.S. patient start forms in the first quarter of 2023 compared to the first quarter of 2022.
  • There were more new U.S. patient start forms in the first quarter of 2023 than in three of the four quarters in 2022.
  • Interest expense was $27.4 million in the first quarter of 2023, compared to $23.8 million in the first quarter of 2022 (+14.9 percent y-o-y).
  • ET today to discuss the financial results and provide a corporate update.

ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results

Retrieved on: 
금요일, 4월 28, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Biologics license application, Capital expenditure, Society, SGO, ASH, Senior, Progression-free survival, Marketing, European Medicines Agency, Survival, Clinical trial, Cancer, Gynecologic Oncology (journal), György Enyedi (geographer), Society of Gynecologic Oncology, NSCLC, Lung cancer, PFS, Mirvetuximab soravtansine, Gilead, Eli Lilly, EMA, Acute myeloid leukemia, PROC, AML, Azacitidine, PIN, Huadong Medicine, Pharmakon—Danish College of Pharmacy Practice, Patient, National Medical Products Administration, Annual general meeting, ImmunoGen, Vertex Pharmaceuticals, ADC, Spacecraft, MAA, Research, FDA, Ovarian cancer, LP, BLA, NMPA, Medicine, Vaccine, Management, Pharmaceutical industry, Mobile phone, Vertex

(Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.
  • Research and development expenses rose to $51.6 million for the quarter ended March 31, 2023 compared to $44.3 million for the quarter ended March 31, 2022.
  • Selling, general and administrative expenses were $40.0 million for the quarter ended March 31, 2023 compared to $16.6 million for the quarter ended March 31, 2022.
  • ImmunoGen had $201.2 million in cash and cash equivalents as of March 31, 2023, compared with $275.1 million as of December 31, 2022.

BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon

Retrieved on: 
화요일, 4월 18, 2023
BioCryst Pharmaceuticals, TD, SOFR, RESEARCH, Pharmakon—Danish College of Pharmacy Practice, Patient, Investment, LP, PARK, Security (finance), Financial services

RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has secured $450 million in committed financing from funds managed by Pharmakon Advisors, LP.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has secured $450 million in committed financing from funds managed by Pharmakon Advisors, LP.
  • BioCryst has elected to draw $300 million of the $450 million available to the company on the closing date.
  • The remaining $150 million of committed capital can be drawn at the company’s option until September 2024.
  • The new five-year credit facility bears interest at the 3-month Secured Overnight Financing Rate (SOFR) + 7.00% (subject to a 1.75% floor).

ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors

Retrieved on: 
목요일, 4월 6, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ImmunoGen, Cancer, Spacecraft, Pharmakon—Danish College of Pharmacy Practice, Interest, Patient, Goldman Sachs, IMGN, Vaccine, Security (finance), LP

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced it has entered into a term loan financing facility for up to $175 million with entities managed by Pharmakon Advisors, LP ("Pharmakon").

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced it has entered into a term loan financing facility for up to $175 million with entities managed by Pharmakon Advisors, LP ("Pharmakon").
  • Proceeds from the agreement will strengthen ImmunoGen's balance sheet and provide the Company with additional capital to support its growth trajectory.
  • Under the terms of the agreement, the loan facility will be available to ImmunoGen in two tranches.
  • Interest will accrue at the three-month Secured Overnight Financing Rate, subject to a 2.75% floor, plus 8.00% per annum.

Evolus Extends Term of Credit Facility with Pharmakon Advisors

Retrieved on: 
목요일, 12월 8, 2022
Luxury, Surgery, Women, Other Health, Biotechnology, Pharmaceutical, Consumer, Health, Cosmetics, Retail, Security (finance), LP, Infection, COVID-19, LIBOR, Pharmakon—Danish College of Pharmacy Practice, Risk management

We are very pleased that Pharmakon supports our vision to become a leading, multi-product aesthetics company by extending the availability of long-term financing.

Key Points: 
  • We are very pleased that Pharmakon supports our vision to become a leading, multi-product aesthetics company by extending the availability of long-term financing.
  • We are proud to financially partner with Evolus as it advances its mission and capitalizes on the underpenetrated aesthetic neurotoxin market, said Pedro Gonzalez de Cosio, CEO of Pharmakon Advisors, LP.
  • A Form 8-K outlining the revised terms of the credit facility was filed today with the Securities and Exchange Commission.
  • Jeuveau and Nuceiva are registered trademarks of Evolus, Inc.
    Hi-Pure is a trademark of Daewoong Pharmaceutical Co, Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005123/en/

UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
목요일, 11월 10, 2022
Medical Devices, Medical Supplies, Hospitals, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Oncology, Adult, Clothing, Risk, Transitional epithelium, Patient Information Advisory Group, Stomach, Company, Pharmakon—Danish College of Pharmacy Practice, Kidney, Recurrence, Blood, Ureter, Swelling, Birth, Urination, Urinary tract infection, SEC, NMIBC, Water, Time, Cancer, Orphan drug, Neoplasm, Patient, UTUC, Urine, COVID-19, Vomiting, Private Securities Litigation Reform Act, Sodium bicarbonate, Bone marrow, Medicine, Clinical trial, Breast milk, Fatigue, Skin, Growth, Abdomen, Nausea, Perforation, NDA, FDA, Trial of the century, Urinary bladder, Fever, Technology, View, Man, Safety, Female, Pain, Transitional cell carcinoma, Nephrectomy, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Tanning (leather), Phosphorus, Generic drug, Mitomycins, Mitomycin C

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005284/en/

UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
목요일, 8월 11, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Nausea, Trial of the century, Female, SEC, Cancer, Clinical trial, Urine, Pain, Blood, Fever, Patient, Swelling, Skin, Clothing, Sodium bicarbonate, Perforation, Breast milk, Disease, Risk, NDA, Technology, Private Securities Litigation Reform Act, UTUC, Patient Information Advisory Group, Recurrence, Ureter, Safety, Water, Birth, Growth, Neoplasm, Man, Fatigue, NMIBC, Bladder cancer, Bone marrow, COVID-19, Stomach, Urinary bladder, Urination, Kidney, Time, Orphan drug, Transitional cell carcinoma, FDA, Vomiting, Abdomen, Nephrectomy, Company, Twitter, View, TURBT, Urinary tract infection, Transitional epithelium, Medicine, Adult, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Tanning (leather), Phosphorus, Generic drug, Pharmakon—Danish College of Pharmacy Practice, Mitomycin C, Mitomycins

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • UroGen are registered trademarks of UroGen Pharma Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005112/en/

GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease

Retrieved on: 
수요일, 6월 29, 2022
Hemolysis, Discovery (observation), Patient, Sickle cell disease, Research, GLOBE, COVID-19, Blood, United States $1 Coin Act of 1997, Oxygen, Polymerization, GBT, FDA, HBS, Securities Act of 1933, Securities Exchange Act of 1934, Tissue, National Heart, Lung, and Blood Institute, PD, Compliance, Pharmacokinetics, SAN, Anemia, Drug Quality and Security Act, SCD, Center, Sickle, Acute chest syndrome, Goal, PK, Private Securities Litigation Reform Act, Capillary, NASDAQ, Lung, Pharmakon—Danish College of Pharmacy Practice, Adult, Stroke, U.S. Securities and Exchange Commission, End organ damage, Disease, United, Registry, Volatile organic compound, Maintenance, Government, Safety, Centers for Disease Control and Prevention, Pharmaceutical industry, HB, Voxelotor

The study ( NCT05431088 ) is a randomized, multicenter Phase 2/3 clinical trial evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of GBT601.

Key Points: 
  • The study ( NCT05431088 ) is a randomized, multicenter Phase 2/3 clinical trial evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of GBT601.
  • Based on compelling preclinical and clinical data, we believe GBT601 has the potential to be a best-in-class therapy for patients with sickle cell disease, said Kim Smith-Whitley, M.D., executive vice president and head of research and development of GBT.
  • The initiation of our Phase 2/3 trial is an important milestone in our efforts to bring GBT601 to patients.
  • GBT601 is being studied in a Phase 1 clinical trial and Phase 2 portion of a Phase 2/3 clinical trial.